Summary

Report Scope
This report presents both qualitative and quantitative data on the current market dynamics and trends in the global neuroprotective agents market. It also assesses pipeline drugs that are under development. The study further includes analyses of various products offered by companies, new strategies implemented by major manufacturers and emerging technologies. It discusses the market prospects for five regions?North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) and includes profiles of leading companies and their strategies.
This report focuses on different indications, such as neurodegenerative disorders, cerebrovascular disease, ophthalmic diseases and central nervous system (CNS) injuries. It segments neurodegenerative disorders into multiple sclerosis, Alzheimer’s disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and Huntington's disease. Ophthalmic diseases are segmented into age-related macular degeneration, glaucoma and other ophthalmic diseases. Based on drug class, the market is divided into immune response modifiers, blood thinning agents, anti-angiogenic agents, antioxidants, ocular hypotensives, anti-dementia agents, anticonvulsants, thrombolytics, anti-Parkinson's agents, antisense agents, anti-amyloid agents and other neuroprotective agents.
On the basis of therapy type, the overall market is segmented into small molecule drugs, monoclonal antibodies, cell therapies, gene therapies and other biotechnology products. The report also covers market projections throughout 2030 and company profiles. By geography, it is segmented into North America, Europe, Asia-Pacific, the MEA, and South America. North America includes the U.S., Canada, and Mexico; Europe includes Germany, the U.K., France, Italy, Spain, and the Rest of Europe; and Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. The study provides market estimates for 2024, with forecasts for 2025 through 2030.
Report Includes
- 54 data tables and 56 additional tables
- An overview of the global market for neuroprotective agents and their therapeutic applications
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the neuroprotective agents, accompanied by a market share analysis by therapy type, indication, drug class, and region
- Analysis of current and future demand in the global neuroprotective agents market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Analysis of drivers, challenges and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants in the neuroprotective agents market, along with their research priorities, product portfolios, global rankings and competitive landscape
- Profiles of major companies within the industry, including Novartis AG, Biogen, Bayer AG, Sanofi, and Teva Pharmaceutical Industries Ltd.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
PESTLE Analysis
Political Factors
Economic Factors
Social Factors
Technological Factors
Legal Factors
Environmental Factors
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to Low)
Bargaining Power of Suppliers (Moderate)
Bargaining Power of Buyers (Moderate)
Threat of Substitute Products (Moderate)
Industry Level of Competitiveness (High)
Chapter 3 Market Dynamics
Overview
Market Drivers
Surge in Neurological Disorders Across the Globe
Rising Prevalence of Neurological Conditions Among the Elderly
Rising Awareness for Neuroprotective Agents
Market Restraints
High Cost of Drug Development
Failure of Clinical Trials in the Neuroprotective Product Line
Market Opportunity
Rising Healthcare Investments
Strategic Implications for a Pharmaceutical or Biotech Company
Chapter 4 Regulatory Landscape
Overview
Regulatory Scenario in the U.S.
Regulatory Scenario in Europe
Regulatory Scenario in Japan
Other Countries
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Precision Medicine in Neurological Disorders
Gene Therapy for Neurological Disorders
Neurodegeneration and Stem Cell Therapy
Nanotechnology in Neuroscience
Conclusion
Pipeline Analysis
Key Takeaways
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown by Indication
Takeaways
Cerebrovascular Disease
Neurodegenerative Disorders
Ophthalmic Diseases
CNS Injury
Market Breakdown by Therapy Type
Takeaways
Small Molecule Drugs
Monoclonal Antibodies
Cell Therapies
Gene Therapies
Other Biotechnology Products
Market Breakdown by Drug Class
Takeaways
Immune Response Modifiers
Blood Thinning Agents
Anti-angiogenic Agents
Antioxidants
Ocular Hypotensive
Anti-Dementia Agents
Anticonvulsants
Thrombolytics
Anti-Parkinson's Agents
Antisense Agents
Anti-Amyloid Agents
Other Neuroprotective Agents
Geographic Region
Market Breakdown by Region
Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa (MEA)
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Analysis
Strategic Initiatives
Chapter 8 Sustainability in Neuroprotective Agents Industry: ESG Perspective
Overview
Key Strategies for Sustainable Drug Manufacturing
Green Chemistry Integration
Energy and Resource Efficiency
Sustainable Raw Material Sourcing
Waste Minimization and Circular Economy Practices
Digitalization and Smart Manufacturing
Regulatory Compliance and Green Certification
Collaborative Innovation and Knowledge Sharing
Sustainable Product Lifecycle Management
ESG Risk Ratings
Concluding Remarks from BCC Research
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ASTRAZENECA
BAYER AG
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
LILLY USA LLC.
MERCK & CO. INC.
NOVARTIS AG
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.
Emerging Start-ups/Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Neuroprotective Agents, by Region, Through 2030
Table 1 : Health Spending, by Country, 2017–2023
Table 2 : List of Few Clinical Trial Drugs of Parkinson’s Disease in Phase 3 and 4, 2025
Table 3 : List of Few Clinical Trial Drugs for Alzheimer’s Disease in Phases 3 and 4, 2025
Table 4 : List of Few Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4, 2025
Table 5 : List of Few Clinical Trial Drugs for Cerebral Stroke in Phase 3 and 4, 2025
Table 6 : List of Granted Patents in Neuroprotective Agent Field, 2022–2024
Table 7 : Global Market for Neuroprotective Agents, by Indication, Through 2030
Table 8 : Global Market for Neuroprotective Agents for Cerebrovascular Disease, by Region, Through 2030
Table 9 : Global Market for Neuroprotective Agents for Neurodegenerative Disorders, by Type, Through 2030
Table 10 : Global Market for Neuroprotective Agents for Neurodegenerative Disorders, by Region, Through 2030
Table 11 : Global Market for Neuroprotective Agents for Ophthalmic Diseases, by Type, Through 2030
Table 12 : Global Market for Neuroprotective Drugs for Ophthalmic Diseases, by Region, Through 2030
Table 13 : Global Market for Neuroprotective Drugs for CNS Injury, by Region, Through 2030
Table 14 : Global Market for Neuroprotective Agents, by Therapy Type, Through 2030
Table 15 : Global Market for Neuroprotective Agents, by Drug Class, Through 2030
Table 16 : List of a Few ASOs as Neuroprotective Agents
Table 17 : Global Market for Neuroprotective Agents, by Region, Through 2030
Table 18 : North American Market for Neuroprotective Agents, by Indication, Through 2030
Table 19 : North American Market for Neuroprotective Agents, by Country, Through 2030
Table 20 : U.S. Market for Neuroprotective Agents, by Indication, Through 2030
Table 21 : Canadian Market for Neuroprotective Agents, by Indication, Through 2030
Table 22 : Mexican Market for Neuroprotective Agents, by Indication, Through 2030
Table 23 : European Market for Neuroprotective Agents, by Indication, Through 2030
Table 24 : European Market for Neuroprotective Agents, by Country, Through 2030
Table 25 : German Market for Neuroprotective Agents, by Indication, Through 2030
Table 26 : U.K. Market for Neuroprotective Agents, by Indication, Through 2030
Table 27 : French Market for Neuroprotective Agents, by Indication, Through 2030
Table 28 : Spanish Market for Neuroprotective Agents, by Indication, Through 2030
Table 29 : Italian Market for Neuroprotective Agents, by Indication, Through 2030
Table 30 : Rest of Europe Market for Neuroprotective Agents, by Indication, Through 2030
Table 31 : Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2030
Table 32 : Asia-Pacific Market for Neuroprotective Agents, by Country, Through 2030
Table 33 : Chinese Market for Neuroprotective Agents, by Indication, Through 2030
Table 34 : Japanese Market for Neuroprotective Agents, by Indication, Through 2030
Table 35 : Indian Market for Neuroprotective Agents, by Indication, Through 2030
Table 36 : Rest of Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2030
Table 37 : South American Market for Neuroprotective Agents, by Indication, Through 2030
Table 38 : South American Market for Neuroprotective Agents, by Country, Through 2030
Table 39 : Brazilian Market for Neuroprotective Agents, by Indication, Through 2030
Table 40 : Argentine Market for Neuroprotective Agents, by Indication, Through 2030
Table 41 : Rest of South American Market for Neuroprotective Agents, by Indication, Through 2030
Table 42 : MEA Market for Neuroprotective Agents, by Indication, Through 2030
Table 43 : MEA Market for Neuroprotective Agents, by Country, Through 2030
Table 44 : Middle Eastern Market for Neuroprotective Agents, by Indication, Through 2030
Table 45 : African Market for Neuroprotective Agents, by Indication, Through 2030
Table 46 : Few Recent Strategic Initiatives, 2024-2025
Table 47 : ESG Risk Rankings for Pharmaceutical Companies, 2023*
Table 48 : Information Sources Used in this Report
Table 49 : Abbreviations Used in this Report
Table 50 : AbbVie Inc.: Company Snapshot
Table 51 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 52 : AbbVie Inc.: Product Portfolio
Table 53 : AbbVie Inc: News/Key Developments, 2023 - 2024
Table 54 : AstraZeneca: Company Snapshot
Table 55 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 56 : AstraZeneca: Product Portfolio
Table 57 : AstraZeneca: News/Recent Developments, 2025
Table 58 : Bayer AG: Company Snapshot
Table 59 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 60 : Bayer AG: Product Portfolio
Table 61 : Bayer AG: News/Key Developments, 2025
Table 62 : Biogen.: Company Snapshot
Table 63 : Biogen: Financial Performance, FY 2023 and 2024
Table 64 : Biogen: Product Portfolio
Table 65 : Biogen: News/Key Developments, 2023-2025
Table 66 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 67 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
Table 68 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 69 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024
Table 70 : Bristol-Myers Squibb Co.: Company Snapshot
Table 71 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 72 : Bristol-Myers Squibb Co.: Product Portfolio
Table 73 : Bristol-Myers Squibb Co.: News/Key Developments, 2023–2025
Table 74 : Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 75 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 76 : Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 77 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 78 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 79 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 80 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
Table 81 : GSK plc: Company Snapshot
Table 82 : GSK plc.: Financial Performance, FY 2023 and 2024
Table 83 : GSK plc: Product Portfolio
Table 84 : GSK plc: News/Key Developments, 2025
Table 85 : Lilly USA LLC.: Company Snapshot
Table 86 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 87 : Lilly USA LLC.: Product Portfolio
Table 88 : Lilly USA LLC.: News/Key Developments, 2024
Table 89 : Merck & Co. Inc.: Company Snapshot
Table 90 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 91 : Merck & Co. Inc.: Product Portfolio
Table 92 : Merck & Co. Inc.: News/Key Developments, 2023
Table 93 : Novartis AG: Company Snapshot
Table 94 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 95 : Novartis AG: Product Portfolio
Table 96 : Novartis AG: News/Key Developments, 2022-2025
Table 97 : Sanofi: Company Snapshot
Table 98 : Sanofi: Financial Performance, FY 2023 and 2024
Table 99 : Sanofi: Product Portfolio
Table 100 : Sanofi: News/Key Developments, 2025
Table 101 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 102 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 103 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 104 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023
Table 105 : UCB S.A.: Company Snapshot
Table 106 : UCB S.A.: Financial Performance, FY 2022 and 2023
Table 107 : UCB S.A.: Product Portfolio
Table 108 : UCB S.A.: News/Key Developments, 2024
Table 109 : List of Few Emerging Startups in the Neuroprotective Agents Market